In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From C.R. Bard

Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip

The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.

BioPharmaceutical Commercial

Samsung Bioepis Opens New HQ To Drive Next-Generation Biosimilars

With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.

Biosimilars Strategy

Samsung Bioepis Calls For Improved Education On Biosimilars

Renewed efforts are needed to educate healthcare industry stakeholders about biosimilars, Samsung Bioepis has insisted, as the firm published a white paper detailing deficiencies in understanding on the part of patients and healthcare professionals.

Biosimilars Strategy

Samsung Bioepis Moves Swiftly To Denosumab Phase III

Samsung Bioepis has announced that its SB16 biosimilar denosumab rival to Amgen’s Prolia has progressed to Phase III trials.

Biosimilars Clinical Trials
See All

Company Information

  • Industry
  • Medical Devices
  • Other Names / Subsidiaries
    • Davol, Inc.
    • Embo Medical Limited
    • Liberator Medical, Inc.
    • Lutonix, Inc.
    • Medafor, Inc.
    • Medicon, Inc.
    • Neomend, Inc.
    • Rochester Medical, Inc.
    • Vascular Pathways, Inc.
    • FlowCardia, Inc.
    • Bridger Biomed, Inc.
UsernamePublicRestriction

Register